The use of electrical stimulation of the upper airway to treat patients with obstructive sleep apnea (OSA) is supported by low-quality evidence.

Nyxoah SA (NYXH) reports a successful Genio system launch in the US, securing key reimbursements and capital, while navigating cost pressures and early-stage market penetration.

Q3 2025 Earnings Call Transcript November 13, 2025 Nyxoah S.A. misses on earnings expectations. Reported EPS is $-0.74 EPS, ...

REGULATED INFORMATION Nyxoah Reports Third Quarter 2025 Financial and Operating Results US launch off to a strong start. First commercial Genio implants completed with widespread payer coverage drives ...

Artisan Partners, an investment management company, released its “Artisan Small Cap Fund” third-quarter 2025 investor letter.

Nyxoah ( ($NYXH) ) has issued an announcement. On November 13, 2025, Nyxoah announced its unaudited third-quarter results for 2025, highlighting ...

LivaNova (Nasdaq: LIVN) today announced its new strategic roadmap and long-range financial plan at its 2025 Investor Day.

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today hosted its 2025 Investor Day and presented its comprehensive strategic roadmap and long-range financial plan.

Forty percent of men snore. We spoke to experts about when snoring could be sleep apnea, and the best remedies to help you ...

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced its participation in the International Surgical Sleep Society (ISSS) 2025 Annual Meeting in Indianapolis. The ...

Medicare is launching a significant new prior authorization initiative under the CMS Innovation Center’s Wasteful and Inappropriate Service Reduction (WISeR) model. Beginning January 2026, select ...